manufacturers of glp 1 drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1 Receptor Agonist Market Size
Description
For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred
Another hurdle is scientific
No evidence of increase in calcitonin concentrations or development of C-cell Malignancy in response to liraglutide for up to 5 years in the LEADER trial
Some people alternate between the two medications over time, using semaglutide for maintenance and tirzepatide for periods when they need additional weight loss
BMJ 379 , e071380 (2022)
